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2089Primary percutaneous coronary intervention (PCI) with
stenting immediately after coronary reperfusion salvage
procedures jeopardizes myocardium, improves prognosis,
and is the current standard of care for acute ST-segment
elevation myocardial infarction (STEMI) (1,2). No-reﬂow
is deﬁned as an acute reduction in myocardial blood ﬂow
despite a patent epicardial coronary artery (3). The patho-
physiology of no-reﬂow involves microvascular obstructionSee page 2099
intervention
STEMI = ST-segment
elevation myocardial
infarction
TIMI = Thrombolysis In
Myocardial Infarction
secondary to distal embolization of clot, microvascular spasm,
and thrombosis (3). No-reﬂow occurs in w10% of cases of
primary PCI and is associated with patient characteristics such
as advanced age and delayed presentation and coronary char-
acteristics such as a completely occluded culprit artery and
heavy thrombus burden (3–7).
No therapies have been shown to prevent no-reﬂow, and
when it occurs, treatment by administration of vasodilator
drugs (8) and intra-aortic balloon counterpulsation therapy
is empirical (2,3,8,9). The rationale for our intervention was
to avoid the potential adverse effects of immediate stenting
when the likelihood of no-reﬂow might be greatest. De-
ferred stent implantation might allow time for reduction in
coronary thrombus burden and recovery of microvascular
function such that the likelihood of no-reﬂow is reduced.
We hypothesized that after initial coronary reperfusion and
normalization of coronary blood ﬂow, brief deferral of
stenting might reduce the occurrence of no-reﬂow compared
with usual care with immediate stenting and increase
myocardial salvage. We investigated this hypothesis in a
real-life clinical setting involving STEMI patients treated
with primary PCI.
Methods
Trial design. We performed a prospective, randomized,
controlled, parallel group trial in STEMI patients enrolled at
a single center between March 11, 2012, and November 21,
2012. The trial was a proof-of-concept trial nested in a
larger prospective cohort study (10).
Participants and eligibility criteria. Patients at risk of no-
reﬂow were selected if radial artery access was used and 1
of the following inclusion criteria were met: 1) clinical history
(3–7) that included myocardial infarction, increased age
(i.e., 65 years of age or older), duration of symptoms >6 h;
2) culprit coronary artery abnormalities (3–7) including
an occluded artery (Thrombolysis In Myocardial Infarction
[TIMI] ﬂow grade 0/1 [11]) at initial angiography,
heavy thrombus burden (TIMI grade 2 or higher [12]),
long lesion length (24 mm), small vessel diameter
(i.e.,2.5 mm); 3) clinical signs of acute microvascular injury
after initial reperfusion (3–7) with persistent ST-segment
elevation >50%.
The exclusion criteria were 1) the absence of normal (TIMI
ﬂow grade 3) coronary blood ﬂow after initial reperfusionwith aspiration thrombectomy
with or without balloon angio-
plasty. The residual severity of
the culprit stenosis was not rele-
vant to participation provided
TIMI ﬂow grade 3 was evident;
2) cardiogenic shock; 3) a contra-
indication to magnetic resonance
imaging (MRI) (e.g., permanent
pacemaker); 4) inability to give
informed consent.
Setting. Consecutive STEMI pa-
tient admissions were screened
for these inclusion and exclusion
criteria. During ambulance transfer to the hospital, the
patients received 300 mg aspirin, 600 mg clopidogrel, and
5000 IU unfractionated heparin (2,9). Catheter laboratory
management is described in the Online Appendix.
Informed consent. Witnessed informed consent was
verbally obtained after coronary reperfusion in eligible
patients in the cardiac catheter laboratory. When the pa-
tient returned to the Coronary Care Unit, a patient infor-
mation sheet approved by the local ethics committee was
provided, and written informed consent was then obtained.
The patients who were not randomized were included in a
registry.
Randomization, implementation, and blinding. Ran-
domization took place immediately after obtaining verbal
consent using a Web-based computer tool with a concealed
random allocation sequence provided by the independent
clinical trials unit and implemented by the catheter labora-
tory physiologist. Randomization was on a 1:1 basis between
usual care with immediate stenting and deferred stenting.
Interventions. The deferred PCI strategy involved an
intention-to-stent 4 to 16 h after initial coronary reperfu-
sion. This time interval was based on a balance between
competing beneﬁts and risks. A short minimum period (4 h)
was adopted, given our concern about the theoretical time-
related risk of coronary reocclusion. In practice, a guideline
of at least 8 h was recommended for the deferred PCI to
permit the beneﬁcial effects of reperfusion and antith-
rombotic therapies and so that all patients could be treated
between 7:00 AM and 11 PM during the ﬁrst 24 h of
admission to ensure that the second procedure occurred at a
time that facilitated a rest period for the patient and the staff.
Finally, an upper limit of 16 h was set to minimize any
prolongation of the hospital admission.
The treatment protocol for deferred patients included
transfer to the Coronary Care Unit, continuous intravenous
infusion of glycoprotein IIb/IIIa inhibitor therapy (tiroﬁban
0.15 mg/kg/min) and administration of subcutaneous low
molecular weight heparin (enoxaparin 1 mg/kg every 12 h)
for up to 16 h. The radial artery sheath used for PCI was
retained or removed according to operator and patient
preference. Arterial blood pressure and the radial sheath site
were monitored in the Coronary Care Unit. All patients also
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Coronary Care Unit.
Usual care included immediate stenting in the catheter
laboratory and intravenous glycoprotein IIb/IIIa inhibitor
therapy for 12 h (tiroﬁban 0.15 mg/kg/min). After the PCI
procedure was completed, the patients returned to the
Coronary Care Unit and were treated with optimal sec-
ondary prevention measures (2).
Outcomes. PRIMARY OUTCOME. The primary outcome was
the incidence of no-/slow-reﬂow (2), deﬁned as absent ﬂow
(TIMI ﬂow grade 0), incomplete ﬁlling (TIMI ﬂow grade
1), or slow-reﬂow but complete ﬁlling (TIMI ﬂow grade 2)
of the culprit coronary artery during or at the end of the PCI
as revealed by the coronary angiogram. Both angiograms
were analyzed for the deferred stenting group and the worst/
lowest ﬂow grade and myocardial blush grade were recorded.
The deﬁnition of no-reﬂow also required the absence of
coronary dissection or obstruction (e.g., due to thrombus)
that could cause a decrease in coronary blood ﬂow (3).
SECONDARY OUTCOMES. The secondary outcomes included
angiographic, electrocardiographic, and MRI parameters.
ANGIOGRAPHIC SECONDARY OUTCOMES. The angiographic
secondary outcomes were no-reﬂow (TIMI ﬂow grade 0/1),
ﬁnal TIMI ﬂow grade (11), corrected TIMI frame count
(12) TIMI myocardial blush grade (13), the occurrence of
intraprocedural thrombotic events (14) (deﬁned as the
development of new or increasing thrombus, abrupt vessel
closure, or distal embolization occurring at any time during
the procedure in the culprit vessel or any signiﬁcant side
branch measuring 2 mm). Embolization was deﬁned as a
distal ﬁlling defect with an abrupt cutoff in one of the pe-
ripheral coronary artery branches of the infarct-related
vessel, distal to the site of angioplasty (9). In the deferred
stenting group, the intended stent strategy at the end of
the ﬁrst procedure was prospectively recorded, and stent
dimensions were compared with the actual stents used in the
second procedure by the same operator (Online Appendix).
In addition, thrombus burden at the start of the second
procedure was compared with the end of the ﬁrst procedure.
Thrombus area was delineated as a contrast ﬁlling defect
using QCA software (Medis QAngio XA software v. 7.2.34.,
Raleigh, North Carolina) and expressed in square millimeters.
ELECTROCARDIOGRAPHIC SECONDARY OUTCOMES. The elec-
trocardiographic secondary outcomes included the occur-
rence of complete (70), partial (30% to <70%), or no
(30%) ST-segment resolution on the electrocardiogram
(ECG) assessed 60 min after reperfusion compared with the
baseline ECG before reperfusion (2,9). In addition, ST-
segment elevation was measured on the baseline ECG
before reperfusion to estimate the extent of initial myocardial
jeopardy with the Aldrich ST-segment elevation score (15).
MRI SECONDARY OUTCOMES. The MRI secondary outcomes
included the occurrence of microvascular obstruction withlate gadolinium enhancement on cardiac MRI 2 days after
reperfusion (16), ﬁnal infarct size at 6 months (16,17),
myocardial salvage (18–20), and myocardial salvage index
(18–20) (both derived using ﬁnal infarct size). Myocardial
salvage (percentage of left ventricular volume) was deﬁned as
the difference between the initial jeopardized area at risk
revealed by T2-weighted MRI at baseline (18–20) and ﬁnal
infarct size revealed by contrast-enhanced MRI at 6 months
(18). The myocardial salvage index was deﬁned as infarct
size at 6 months indexed to the initial area at risk (19).
SAFETY OUTCOMES. The potential risks of the second cathe-
terization (e.g., bleeding, contrast nephropathy) and procedure-
related complications such as intraprocedural thrombotic
events and health outcomes were included as safety outcomes.
Clinical outcome measures included the occurrence of
heart failure, reinfarction, bleeding, and cardiac death during
the index admission and after discharge, as deﬁned in the
Clinical Event Committee Charter (Online Appendix).
Myocardial infarction and reinfarction were deﬁned ac-
cording to the Universal Deﬁnition of Myocardial infarction
(21). All potential clinical events were adjudicated blinded to
treatment allocation by an independent clinical event com-
mittee comprising 3 cardiologists who were not afﬁliated
with our hospital (Online Appendix).
All study participants were followed for a minimum of 8
months after discharge. Information on adverse events was
obtained by clinical review of the patients and primary and
secondary care records during follow-up.
Coronary angiogram acquisition and analyses. Coronary
angiograms were acquired during usual care with cardiac
catheter laboratory x-ray (Innova, GE Healthcare, Fairﬁeld,
Connecticut) and information technology equipment (Cen-
tricity, GE Healthcare). The angiograms underwent inde-
pendent analysis in the Cardiovascular Research Foundation
Angiographic Core Laboratory in New York, New York, by
staff blinded to treatment assignment (Online Appendix).
ECG and MRI acquisition and analyses. The ECGs
underwent independent blinded analysis by an observer
trained in the Glasgow ECG Core Laboratory (Glasgow,
United Kingdom) (Online Appendix). Cardiac MRI was
performed w2 days after reperfusion on a Siemens MAG-
NETOM Avanto (Erlangen, Germany) 1.5-T scanner with
a 12-element phased array cardiac surface coil. The imaging
protocol included cine MRI with steady-state free preces-
sion, T2-weighted edema imaging, and early and late gad-
olinium enhancement imaging (Online Appendix) (16–20).
The initial area at risk was delineated with T2-weighted
MRI (20). Microvascular obstruction was deﬁned as a
central dark zone on early contrast enhancement imaging 1,
3, 5, and 7 min post-contrast injection and present within
an area of late gadolinium enhancement (16). Myocardial
infarction was imaged using a segmented phase-sensitive
inversion recovery turbo fast low-angle shot (17) radio-
frequency pulse sequence 15 min after intravenous injection
of 0.15 mmol/kg of gadoterate meglumine (Dotarem
Figure 1 Study Flow Diagram
MRI ¼ magnetic resonance imaging; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.
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2091[gadoterate meglumine], Guebert S.A., Villepinte, France).
The MRI scans were analyzed by observers blinded to the
treatment group allocation of the study participants.
Sample size. Based on a clinical audit in our hospital and a
literature review (4–6), we estimated that the incidence of
no-/slow-reﬂow (TIMI ﬂow grade 2) during primary PCI
would be 40% in selected patients with 1 of our predeﬁned
risk factors and 10% in the deferred PCI group. A minimum
of 84 patients (42 per group) would provide 85% power to
reject the null hypothesis with a type I error of 0.05.
Statistical methods. Mean  SD were used to summarize
approximately normally distributed continuous data. Me-
dian (interquartile range [IQR]) or geometric mean  SD
were used to describe skewed continuous data. Number and
percentage were used to summarize categorical data. All
tests were 2-tailed and assessed at the 5% signiﬁcance level.
Comparisons of continuous variables used paired or un-
paired t tests for normally distributed data or the Wilcoxon
or t test after logarithmic transformation for skeweddata. Differences in proportions were assessed using the
Fisher exact or McNemar test for paired comparisons.
Odds ratio and 95% conﬁdence interval for treatment ef-
fects outcomes were assessed using exact logistic regression
for binary outcomes and ordinal logistic regression for
ordinal outcomes. All statistical analyses were performed
using R version 2.15.2 (R Project for Statistical Computing,
Vienna, Austria) or SAS version 9.2 (SAS Institute, Cary,
North Carolina) (or higher versions of these programs).
The Robertson Center for Biostatistics acted as an inde-
pendent coordinating center for randomization and its stat-
isticians conducted the analyses. The study was monitored
for safety by the sponsor. All serious adverse events were
prospectively reported to the Pharmacovigilance Unit of the
Clinical Trials Unit. The trial was approved by the National
Research Ethics Service (reference 10/S0703-28). The reg-
istry was approved by the hospital’s Caldicott Guardian
and Clinical Governance ofﬁce. The trial sponsor is the
National Waiting Times Center Board, NHS Scotland.
Table 1 Baseline Clinical and Angiographic Characteristics of All-Comers
Characteristics
Randomly Assigned Groups
Registry*
(N ¼ 310)
Immediate Stenting
(n ¼ 49)
Deferred Stenting
(n ¼ 52)
Clinical
Age, yrs 61.7  12.2 57.6  10.9 61.4  12.9
Male 36 (73.5) 34 (65.4) 196 (63.2)
Heart rate, beats/min 83  17 77  17 83  32
Systolic blood pressure, mm Hg 138  27 141  24 131  28*
Diastolic blood pressure, mm Hg 79  17 83  11 77  16*
Diabetes mellitus,y 6 (12.2) 7 (13.5) 30 (9.7)
Previous MI 2 (4.1) 5 (9.6) 30 (9.7)
Previous PCI 2 (4.1) 2 (3.8) 21 (6.8)
Heart failure, Killip class at presentationy
I 35 (71.4) 38 (73.1) d
II 13 (26.6) 12 (23.1) d
III 1 (2.0) 2 (3.8) d
Procedure
Time from symptom onset to reperfusion
(ﬁrst balloon or aspiration thrombectomy), min
183 (131–337) 166 (124–276) 184 (124–338)
Time from symptom onset to reperfusion >12 h 5 (10.2) 1 (1.9) 6 (5.9)
Coronary angiography
No. of diseased arteries
1 26 (55.3) 22 (45.8) d
2 15 (31.9) 17 (35.4) d
3 6 (12.8) 9 (18.8) d
Culprit artery
LAD 18 (36.7) 15 (28.8) 131 (42.3)*
LCX 6 (12.2) 11 (21.2) 42 (13.5)*
RCA 25 (51.1) 25 (48.1) 132 (42.6)
Vein graft 0 (0.0) 1 (1.9) 2 (0.6)
Left main 0 (0.0) 0 (0.0) 3 (1.0)
TIMI coronary ﬂow grade pre-PCIz
0/1 39 (79.6) 40 (76.9) 200 (64.5)*
2 7 (14.3) 6 (11.5) 43 (13.9)
3 3 (6.1) 6 (11.5) 67 (21.6)*
Lesion length, mm* 15.4 (11.2–20.6) 13.5 (11.2–17.8) d
Coronary artery diameter at the
start of the procedure, mm*
Proximal to the culprit lesion 3.2  0.7 3.2  0.6 d
Distal to the culprit lesion 2.7  0.6 2.7  0.6 d
Thrombus present,* 47 (95.9) 51 (98.1) 284 (91.6)
Thrombus area, mm2* 13.0 (8.3–20.2) 19.9 (12.0–1.3) d
TIMI thrombus grade
0/1 21 (42.9) 22 (42.3) 151 (48.9)
2 6 (12.2) 6 (11.5) 62 (20.1)
3 10 (20.4) 7 (13.5) 60 (19.4)
4 12 (24.5) 17 (32.7) 36 (11.7)
Jeopardized myocardium by the ECG
Aldrich score (% left ventricle)x (14)
20 (17–30) 19 (15–26) d
Continued on the next page
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A total of 411 patients were treated with primary PCI be-
tween March 11, 2012 and November 21, 2012, and all of
these patients were included in a registry (Fig. 1, Table 1).
Of these, 101 patients (mean age, 60 years; 69% male) were
randomized (52 in the deferred stenting group, 49 in theimmediate stenting group (Fig. 1) by 8 of 13 cardiologists
(62%). The trial stopped when all patients had a minimal
follow-up period of 6 months, and all randomized patients
were included in the analysis.
Immediate versus deferred stenting groups. ANGIO-
GRAPHIC FINDINGS. The incidence of no-/slow-reﬂow after
stenting (primary endpoint) was signiﬁcantly lower in the
Table 1 Continued
Characteristics
Randomly Assigned Groups
Registry*
(N ¼ 310)
Immediate Stenting
(n ¼ 49)
Deferred Stenting
(n ¼ 52)
Procedure details
Aspiration thrombectomy 42 (85.7) 46 (88.5) d
Glycoprotein IIb/IIIa inhibitor therapy 46 (98.9) 51 (98.1) d
Pre-dilation 36 (73.5) 46 (88.5) d
Post-dilation 35 (71.4) 30 (57.7) d
Final inﬂation pressure, kPa 17.4  2.4 16.4  3.2 d
Intracoronary adenosine therapy 4 (8.2) 3 (5.8) d
No. of stents
0 0 3 (5.8) d
1 39 (79.6) 33 (63.5) d
2 9 (18.4) 16 (30.8) d
3 1 (2.0) 0 d
Contrast volume, ml 205 (172–250) 278 (238–312) d
Values shown are n (%), mean  SD, median (interquartile range) . *The following clinical characteristics differed between the registry patients and
the randomly assigned patients who were enrolled in the trial: systolic blood pressure (p ¼ 0.003), diastolic blood pressure (p ¼ 0.022), TIMI
thrombus grade 4 (p < 0.0001), and TIMI ﬂow grade pre-PCI (TIMI ﬂow grade 0/1, p ¼ 0.015; TIMI ﬂow grade 3, p ¼ 0.007). Quantitative coronary
and electrocardiographic analyses were done in the randomized patients but not in the registry patients. yDiabetes mellitus was deﬁned as a history
of diet-controlled or treated diabetes. Killip classiﬁcation of heart failure after acute myocardial infarction: class I, no heart failure; class II, pulmonary
rales or crepitations, a third heart sound, and increased jugular venous pressure; class III, acute pulmonary edema; class IV, cardiogenic shock. A
diseased artery was deﬁned as an epicardial artery (2 mm) with 1 lesions 50% of the reference vessel diameter. zTIMI coronary ﬂow grade pre-
PCI was not assessable in 1 patient in the immediate stenting group. Intracoronary adenosine (10 to 30 mg) was administered as bolus therapy
during primary PCI as clinically indicated for reduced coronary ﬂow. The clinical and treatment characteristics of the patients included in the im-
mediate stenting group and the deferred stenting group were similar except for the total volume of contrast, which was greater in the deferred
stenting group (p < 0.0001). Procedure details and outcomes include the ﬁrst and second procedures in the deferred stenting group. Two deferred
stenting patients experienced culprit artery reocclusion before the planned second procedure. The coronary ﬂow grades at the end of the ﬁrst
procedure and at the start of the second procedure differed in 3 other deferred stenting patients as follows: 2 patients changed from TIMI ﬂow grade
3 to 2, and 1 patient changed from TIMI ﬂow grade 2 to 3. None of the patients received bail-out or covered stents. xST-segment elevation
was measured on the baseline ECG before reperfusion to estimate the extent of initial myocardial jeopardy with the Aldrich ST-segment elevation
score (14).
ECG ¼ electrocardiogram; LAD ¼ left anterior descending artery; LCA ¼ left circumﬂex artery; MI ¼ myocardial infarction; PCI ¼ percutaneous
coronary intervention; TIMI ¼ Thrombolysis In Myocardial Infarction grade.
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2093deferred stenting group (odds ratio: 0.16; 95% conﬁdence
interval: 0.04 to 0.59; p ¼ 0.006) (Table 1). Distal emboli-
zation and intraprocedural thrombotic events were also less
frequent in the deferred stenting group (Table 2). After
stenting, TIMI ﬂow grade 3 and myocardial blush grade were
higher in the deferred stenting group (Table 2). Within the
deferred stenting group, there was a signiﬁcant reduction in
the proportion of patients with angiographic evidence of
thrombus at the start of the second versus the ﬁrst procedure
(98.1% vs. 62.7%; p < 0.0001). Coronary thrombus area
reduced signiﬁcantly between the end of the ﬁrst and start of
the second angiograms (geometric mean for the ratio of the
thrombus areas: 0.67; 95% conﬁdence interval: 0.53 to 0.85).
Compared with the intended stent strategy at the end of the
ﬁrst procedure, there was a signiﬁcant increase in maximal
stent diameter (in millimeters) (3.0 [IQR: 3.0 to 3.5] versus
3.5 [IQR: 3.0 to 4.0]; p< 0.0001) and length (in millimeters)
(28 [IQR: 18 to 32] vs. 28 [20 to 40]; p ¼ 0.002) evaluated
by the same operator in the second procedure (Online
Appendix). Three deferred stenting patients did not receive
a stent. In 1 patient, repeat arterial access was not possible
because of peripheral arterial disease. In the other 2 patients,
the culprit lesions had only minimal residual stenosis.
MRI FINDINGS. The MRI results 2 days and 6 months post-
MI are described in Table 3. Compared with immediatestenting, myocardial salvage (percentage of left ventricular
mass) (19.7% [IQR: 13.8% to 26.0%] vs. 14.7% [IQR: 8.1%
to 23.2%]; p ¼ 0.027) and salvage index (68% (IQR: 54% to
82%) vs. 56% (IQR: 31% to 72%); p ¼ 0.031) at 6 months
were greater in the deferred stenting group (Fig. 2).
Adverse events and safety. IN-HOSPITAL EVENTS AFTER
RANDOMIZATION. In the deferred stenting group, recurrent
ST-segment elevation myocardial infarction before stenting
occurred in 2 patients. One patient had a severe intramural
dissection within the culprit lesion in the left anterior
descending coronary artery associated with absent ﬂow in
a large diagonal side branch. Five hours after initial reperfusion,
the patient experienced recurrent chest pain associated with
anterior ST-segment re-elevation. Repeat coronary angiog-
raphywas performedwithin 30min and conﬁrmed reocclusion
of the culprit artery. The patient received a stent, and his
subsequent clinical course was uncomplicated. A second pa-
tient who inadvertently had not received lowmolecular weight
heparin therapy in the Coronary Care Unit experienced a
reinfarction before stenting. This patient was treated with a
stent within 30 min of symptom onset and had an uncom-
plicated clinical course. One additional patient experienced an
abrupt culprit artery closure and intraprocedural thrombotic
event due to a guidewire-related dissection.
There were no bleeding events or in-hospital deaths.
There was a greater volume of contrast used in the deferred
Table 2 Primary and Secondary Angiographic and Electrocardiographic Outcomes
Outcome
Randomly Assigned Groups
Odds Ratio
(95% CI) p Valuey
Registry
(N ¼ 310)
Immediate
Stenting
(n ¼ 49)
Deferred
Stenting
(n ¼ 51)*
Primary outcome
No- or slow-reﬂow (TIMI 0 to 2)z
Yes 14 (28.6) 3 (5.9) 0.16 (0.03–0.63) 0.005 45 (14.5)
Secondary angiographic outcomes
No-reﬂow (TIMI grade 0 or 1)
Yes 7 (14.3) 1 (2.0) 0.12 (0.03–1.02) 0.052 16 (5.2)
Final TIMI coronary ﬂow grade post-
PCIx
3 39 (79.6) 50 (98.0) 273 (88.6)
2 6 (12.2) 0 (0.0) 0.08 (0.01–0.65) 0.018 25 (8.1)
0/1 4 (8.2) 1 (2.0) 10 (3.2)
Final TIMI myocardial blush
grade post-PCIk
Missing 0 1
3 26 (53.1) 40 (80.0)
2 18 (36.7) 9 (18.0) 0.28 (0.11–0.65) 0.004 d
0/1 5 (10.2) 1 (2.0)
No- or slow-reﬂow (TIMI grades 0–2),
with MBG 1
Missing 0 1
Yes 5 (10.2) 1 (2.0) 0.18 (0.00–1.72) 0.195
No- or slow-reﬂow (TIMI grades 0–2),
with MBG 2
Missing 0 1
Yes 12 (24.5) 2 (4.0) 0.13 (0.01–0.64) 0.007
All intraprocedural thrombotic
events
28 9 d d 68
Patients with at least 1
intraprocedural
thrombotic event
16 (32.7) 5 (9.8) 0.23 (0.06–0.73) 0.010 63 (20.3)
Distal embolization 10 (20.4) 1 (2.0) 0.08 (0.02–0.60) 0.006 5 (1.3)
Other secondary outcome
ECG: resolution of ST-segment
elevation 60 min post-PCI
d
Complete, 70% 19 (38.8) 26 (50.0)
Partial, 30% to <70% 21 (42.9) 15 (28.8) 0.77 (0.37–1.6) 0.484
None, 30% 9 (18.4) 11 (21.2)
Values are n (%). At the end of the ﬁnal PCI, the percentage of diameter stenosis, ﬁnal stent diameter, reference vessel diameter ratio, and corrected
TIMI frame count were similar in both groups. In the deferred group, TIMI coronary ﬂow grade, reference vessel diameters, ﬁnal corrected TIMI frame
count, and myocardial blush grade at the start of the second procedure compared with the end of the ﬁrst procedure were similar in both groups.
*One of the patients in the deferred group did not have a second procedure because of failed vascular access; therefore, data from 51 participants in
the deferred group have been included in the intention-to-treat analysis. yThe p value is the comparison between the immediate stenting group and
the deferred group. Compared with the immediate stenting group, a lower proportion of patients in the registry group experienced no-/slow-reﬂow (45
[14.5%] vs. 14 [28.6%]; p ¼ 0.01). zNo- or slow-reﬂow was assessed at any time during or at the end of PCI. xTIMI coronary ﬂow grade was assessed
post-PCI, at the end of the procedure, and was not assessable in 2 patients in the deferred group. The odds ratios for coronary ﬂow grade post-PCI are
the odds ratio for achieving a lower score in the deferred group relative to the immediate stenting group. The odds ratio calculations are described in
the Methods section. kTIMI MBG was assessed post-PCI, at the end of the procedure, and was not assessable in 2 patients in the deferred group. The
odds ratios for TIMI MBG post-PCI are the odds ratio for achieving a lower score in the deferred group relative to the immediate stenting group.
Corrected TIMI frame count was not assessable in 9 patients in the immediate stenting group and in 3 patients in the deferred group (data not
shown).
CI ¼ conﬁdence interval; MBG ¼ myocardial blush grade; other abbreviations as in Table 1.
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2094stenting group (278 ml (IQR: 238 ml to 312 ml) vs. 205 ml
(IQR: 170 ml to 250 ml); p < 0.0001). No cases of contrast
nephropathy occurred.
Post-discharge events. The duration of follow-up was 352
 79 days from randomization. Three patients in the de-
ferred stenting group and 1 patient in the immediatestenting group experienced a non-STEMI. Two additional
patients in the immediate stenting group were hospitalized
with unstable angina, 1 of whom was treated with PCI.
The incidence of recurrent MI post-randomization was
similar for the 2 groups. In the deferred stenting group,
2 patients experienced an acute reinfarction during the
Figure 2 Two Patients With Acute Anterior STEMI
One patient was treated by conventional primary PCI with immediate stenting and the other was treated with initial aspiration thrombectomy and then deferred stenting. Each
patient had similar ischemic times (147 min and 163 min), and both were treated with similar antithrombotic therapies including 300 mg aspirin, 600 mg clopidogrel, 5,000 IU
heparin, and intravenous tiroﬁban. (A) Usual care with immediate stenting. The angiogram (left) revealed proximal occlusion of the left anterior descending artery (green arrow,
Thrombolysis In Myocardial Infarction [TIMI] grade 0 ﬂow). Primary PCI was complicated by no-reﬂow (TIMI grade 1 ﬂow). Two days later, cardiac MRI was performed. Cine MRI
(middle left) revealed an extensive anteroapical left ventricular wall motion abnormality. Matched diastolic phase images obtained using late gadolinium enhancement imaging
(middle right) revealed a transmural infarction with microvascular obstruction (orange arrows). The area at risk revealed by T2-weighted imaging (right) was 42.2% of left
ventricular mass, and the acute infarct size revealed by late gadolinium enhancement (middle right) was 39.6%. Microvascular obstruction depicted as the central dark zone
within the infarct territory was 8.2% of the left ventricular mass. The left ventricular ejection fraction and end-systolic volume were 43.7% and 52.3 ml/m2, respectively.
Six-month follow-up MRI revealed that the ﬁnal infarct size was 32.1% of the left ventricular mass, and therefore myocardial salvage was 10.1%. (B) Deferred PCI. The angiogram
(left) revealed a proximal occlusion of the left anterior descending artery (green arrow, TIMI grade 0 ﬂow). Primary PCI in the left anterior descending coronary artery with deferred
stent implantation was uncomplicated. Two days later, cardiac MRI was performed. Cine MRI (middle left) revealed an extensive anteroapical left ventricular wall motion
abnormality. Despite similar ischemic times in both patients, this patient had minimal evidence of infarction on late gadolinium enhancement imaging (middle right) and no
microvascular obstruction. The acute infarct size was 8.4% of the left ventricular mass. The area at risk (right) was similar between cases, at 43.1%, as was the left ventricular
ejection fraction and normalized end-systolic volume, measured at 43.5% and 57.1 ml/m2, respectively, consistent with stunned but viable myocardium. Six-month follow-up
MRI revealed that the ﬁnal infarct size was 1.7% of the left ventricular mass, and therefore myocardial salvage was 41.4%.
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2095index admission, and 3 patients experienced a non-STEMI
during follow-up, whereas in the usual care group, 1 patient
experienced a non-STEMI during follow-up (p ¼ 0.108).
There was 1 noncardiovascular death due to small cell
lung carcinoma in the deferred stenting group. All of these
events are described in more detail in the Online Appendix.Discussion
We implemented a novel strategy to prevent no-reﬂow in
at-risk patients with STEMI undergoing primary PCI.
A simple approach was adopted for treatment stratiﬁcation
and randomization by the cardiologist. We identiﬁed pa-
tients with initial evidence of successful reperfusion and with
clinical risk factors for no-reﬂow, and from these patients,
the study participants were randomized to immediate
stenting or to an intention-to-stent strategy within 4 to 16 h,
including prolonged antithrombotic therapy. The strategy ofdeferred stenting in primary PCI represents a radical change
from standard care.
Our trial provided new knowledge on primary PCI. We
observed that deferred completion of PCI in selected
STEMI patients reduced no-reﬂow, distal embolization,
and intraprocedural thrombotic complications compared
with conventional treatment with immediate stenting. Final
coronary ﬂow grade and myocardial blush grade were also
better in the deferred stenting group. Two patients in the
deferred stenting group experienced early recurrent
myocardial infarction before the second procedure. During
longer term follow-up, myocardial salvage measured with
cardiac MRI was signiﬁcantly greater in the deferred
stenting group. In other words, when indexed to the initial
extent of jeopardized myocardium (i.e., the ischemic area at
risk), ﬁnal infarct size was smaller in the patients random-
ized to deferred PCI. The MRI results obtained after 6
months of follow-up indicate a beneﬁcial treatment effect
Table 3
Contrast-Enhanced Cardiac MRI Findings During
Index Hospitalization and After 6-Month Follow-Up
Immediate
Stenting
Deferred
PCI* p Value
MRI 2 days post-MI n ¼ 47 n ¼ 48
Microvascular obstruction 29 (61.7) 23 (47.9) 0.155
MRI 6 months post-MI n ¼ 44 n ¼ 45
Myocardial salvage, % of
left ventricular massy
14.7 (8.1–23.2) 19.7 (13.8–26.0) 0.027
Myocardial salvage
index, %
56 (31–72) 68 (54–82) 0.031
Infarct size, % of
left ventricular mass
14.3 (6.3–20.3) 9.0 (4.3–16.0) 0.181
Values are n (%) or median (interquartile range). The initial area at risk (percentage of left ven-
tricular volume) revealed by MRI 2 days after MI was similar in patients randomized to immediate
stenting (31.6 [IQR: 20.8 to 37.4]) compared with patients randomized to deferred PCI (28.4 [IQR:
23.4 to 36.6]; p ¼ 0.577). *Compared with the immediate stenting group, favorable directional
changes were observed in the deferred PCI group for left ventricular end-systolic volume, left
ventricular end-diastolic volume, and ejection fraction (their changes at 6 months from baseline
[data not shown]). yWhen considering the degree of myocardial salvage according to speciﬁc
patient characteristics (inclusion criteria), myocardial salvage (percentage of left ventricular mass)
was signiﬁcantly higher in the deferred stenting group compared with the immediate stenting group
in patients with persistent ST-segment elevation on the electrocardiogram post-reperfusion
and patients presenting with an occluded artery (19.05 [IQR: 13.57 to 26.52] vs. 12.60 [IQR:
6.20 to 23.20]; p ¼ 0.039 and 19.70 [IQR: 13.70 to 26.40]vs. 12.55 [IQR: 6.52 to 19.67]; p ¼
0.001, respectively). There was directional consistency with a favorable treatment effect on salvage
for deferred stenting across all the inclusion criteria (except for lesion length). The time from
randomization to MRI was 60 (IQR: 18 to 97) h and 55 (IQR: 22 to 90) h in the immediate stenting
and deferred groups, respectively.
MRI ¼ magnetic resonance imaging; other abbreviations as in Table 1.
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2096that was sustained over time. Because myocardial salvage is a
prognostically validated therapeutic target in primary PCI
(2,9), the favorable long-term effect of deferred stenting on
myocardial salvage is clinically relevant.
We also found that in the deferred PCI group, the
approach to PCI differed at the second procedure compared
with the ﬁrst for the same operator. The maximal stent
diameter in the second procedure was 0.5 mm greater and
the range of stent length was greater. Three-fourths of pa-
tients had an increase in stent diameter. These observations
indicate that vessel dimensions are greater at the second
procedure compared with the ﬁrst, in keeping with attenu-
ation of coronary artery tone with time from reperfusion.
Our trial results reﬂect a balance of potential beneﬁts and
potential risks. The trial was conducted during usual care,
and our intervention was based on simple clinical eligibility
criteria. The antithrombotic strategy involved a mechanical
component (i.e., deferral of stent implantation to avoid/
minimize thrombus embolization) and a therapeutic
component based on prolonged treatment with low molec-
ular weight heparin (1 mg/kg) and glycoprotein IIb/IIIa
inhibitor therapy during the interval between the ﬁrst and
second PCI procedures. Glycoprotein IIb/IIIa inhibitor
therapy is an evidence-based antithrombotic treatment (2,9)
and was included in therapeutic strategy to reduce thrombus
burden before stent implantation in the deferred stenting
group (9). Although these treatments also increase the risk
of bleeding, no bleeding problems occurred in the deferred
stenting group, probably because radial artery access was
used in all patients. Accordingly, our strategy has the po-
tential to be widely applicable.Our strategy was based on selection of patients with at
least 1 clinical and/or angiographic risk factor for no-reﬂow
(4–6). We believed that the intervention would not be
appropriate in “all-comers” for 3 reasons. First, the efﬁcacy
of deferred stenting was likely to be greatest in the patients
at highest risk of no-/slow-reﬂow. Second, the risk of
recurrent myocardial infarction could not be mitigated in
patients who were at low risk of no-reﬂow on clinical
grounds. Third, a strategy that involved all-comers would be
difﬁcult to implement due to the large number of additional
second procedures. To assess whether clinicians could
stratify patients at risk of no-reﬂow, information on all-
comers was collected, and those who were not randomized
were included in a registry.
The clinical risk proﬁles of the randomized and registry
patients differed. Compared with the registry patients,
TIMI thrombus grade 4 and an occluded culprit artery
(TIMI ﬂow grade 0/1) were much more common in the
trial patients. Greater thrombus burden and an occluded
culprit artery are both associated with large infarct size (22)
and an adverse prognosis (2,9). These baseline differences
between randomized and registry patients can be explained
by appropriate risk stratiﬁcation and patient selection by
the cardiologists at the time of primary PCI.
Compared with the randomized trial participants, the no-/
slow-reﬂow rate of 14.5% in the registry was nearly half of the
incidence of this event observed in the immediately stented
patients and more than double the incidence of no- or slow-
reﬂow in the deferred stenting group. This ﬁnding indicates
that the patient selection approach correctly identiﬁed a
subgroup of STEMI patients in whom the incidence of no-/
slow-reﬂow was lower (Table 2). Furthermore, the incidence
of no-/slow-reﬂow in the subgroup of registry patients who
were eligible for inclusion but not randomized due to patient
or physician preference (Fig. 1) was 23.4%, which was very
similar to the rate observed in the immediate stenting group.
Although the observed rate of no-reﬂow in the immediate
stenting group was lower than predicted, we still observed a
signiﬁcant reduction in the deferred stenting group.
Our study was performed during normal emergency care.
However, as might be expected with a new intervention that
represents a radical change from standard care, patient
enrollment was inﬂuenced by physician preference, and in
the absence of clinical evidence to support this strategy, 5 of
13 cardiologists in our primary PCI service did not
randomize any patients.
Thrombus is mechanistically involved in no-reﬂow, and
stent implantation may cause distal embolization of clot and
microvascular thrombosis (23). Based on the rationale for
our intervention, we examined whether coronary thrombus
burden might be lower at the start of the second PCI
compared with the start of the ﬁrst procedure (when stenting
is normally performed), and this indeed was the case.
Furthermore, thrombus in the culprit artery had dissipated
during the intervening period. Thus, coronary stent im-
plantation in the deferred stenting group of patients
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2097occurred when thrombus burden was less, and so the sub-
strate for distal embolization and microvascular thrombosis
had diminished. This may explain the lower incidence of no-
reﬂow in the deferred stenting group.
Two patients in the deferred stenting group had early
recurrent myocardial infarction. One of these patients had a
complex culprit lesion with an intramural dissection (24) and
persistently reduced side-branch ﬂow (TIMI grade 1). The
other patient was a protocol violation as he had not received
low molecular weight heparin after the initial procedure.
Both patients were treated with PCI expeditiously and
without complication. These events contain learning that
should be used to optimize the design of a future clinical
trial. For example, persistent ﬂow reduction (TIMI grade
0/1) in the side branch of a culprit bifurcation lesion would
be an exclusion criterion. Overall, the balance of the beneﬁt
of reduced no-reﬂow versus the risk of recurrent myocardial
infarction needs to be tested in a large multicenter, ran-
domized, controlled trial.
Therapeutic strategies for the prevention and treatment
of no-reﬂow have not improved clinical outcomes in large
multicenter randomized trials (2,8,25–27).Other clinical trials
with different approaches to deferred stenting in primary PCI
include MIMI (Minimal Invasive Procedure for Myocardial
Infarction [NCT01360242]), PRIMACY (Primary Reper-
fusion Secondary Stenting Trial [NCT01542385]), and
DANAMI-3 (DANish Study of Optimal Acute Treatment
of Patients With ST-elevation Myocardial Infarction
[NCT01435408]). Recent studies (28–31), including 3 non-
randomized case series (28–30) and a systematic review (31),
support the notion that deferred stenting may be safe in
appropriately selected STEMI patients.
Implications for clinical practice. Our strategy of deferred
stenting in selected STEMI patients with risk factors for no-
reﬂow represents a potential new treatment paradigm. The
strategy involves a balance between competing risks and
beneﬁts that merits prospective evaluation in a large clinical
trial. On the one hand, we have shown that deferred stenting
reduces no-reﬂow and increases myocardial salvage. On the
other hand, there may be an increased risk of early recurrent
STEMI. Based on our experience, the design of the inter-
vention should be adapted to further mitigate the risk of
early coronary reocclusion (e.g., a patient with side-branch
occlusion would not be suitable). A deferred stent strategy
involves a second procedure, and so procedure-related costs
may be higher. Our study design timed the second proce-
dure 4 to 16 h after the ﬁrst to keep the second procedure
within working hours and thus optimize feasibility. On the
other hand, the strategy has the potential to reduce health-
care costs overall by reducing the clinical consequences of
no-reﬂow (e.g., heart failure and its related cost burden).
Only a large clinical trial designed to assess patient experi-
ence, health outcomes, quality of life, and cost-effectiveness
can address these uncertainties.
Study limitations. Investigators and patients were un-
blinded in our study. For this reason, the primary andsecondary outcomes underwent independent analysis blind
to treatment group assignment to prevent ascertainment
bias. Our initial estimates for the expected incidences of no-/
slow-reﬂow were slightly higher than the observed rates.
The reasons for this may be multifactorial and may reﬂect
the effect of core laboratory adjudication over investigator-
reported events. Our study design did not include an
angiographic control in the immediate stenting group, but
we do not think that this is relevant because the occurrence
of no-reﬂow and other angiographic sequelae, such as
intraprocedural thrombotic events, is due to the effect of
PCI, so additional invasive angiography in the control group
seems unnecessary. The minimal delay of 4 h to the second
procedure in the deferred stenting group was relatively short
and may not have been sufﬁcient time to permit signiﬁcant
reduction in thrombus size. Although 2 patients experienced
recurrent STEMI, their outcome was favorable. The rate of
recurrent ischemia in the deferred stenting group was low,
and, considering the limited sample size, we cannot exclude
the possibility that this was due to chance. TIMI frame
count was not assessable in several of the angiograms.
Because deferred stenting involves a second invasive proce-
dure with radiographic contrast medium, on safety grounds,
radial artery access is recommended and advanced peripheral
vascular disease and severe renal dysfunction (e.g., glomer-
ular ﬁltration rate <30 ml/min) should be exclusion criteria.
Glycoprotein IIb/IIIa inhibitor therapy and unfractionated
heparin were used rather than bivalirudin (2), and because
the former antithrombotic combination therapy almost
certainly remains the most common combination used
worldwide, we think that our results are generalizable. Our
standard-care antiplatelet strategy involved oral clopidogrel
given at the time of the ﬁrst medical contact (2). Because
more effective antiplatelet drug therapies are available, such
as prasugrel, ticagrelor, and cangrelor (2), we postulate that
the efﬁcacy and safety of the deferred strategy could be
further enhanced with one of these drugs instead of clopi-
dogrel. Some of the clinical characteristics (e.g., time from
symptom onset to reperfusion >12 h) and outcomes (e.g.,
some MRI and electrocardiographic parameters) were
numerically, but not statistically, different between treat-
ment groups, which may reﬂect the limited sample size.
Conclusions
For the ﬁrst time, we conducted a proof-of-concept trial and
found that deferred stenting in primary PCI reduced no-
reﬂow and increased myocardial salvage compared with con-
ventional primary PCIwith immediate stenting. Two patients
had recurrent myocardial infarction, which represents
important balancing information on potential risks. The
strategy is simple, pragmatic, and potentially widely appli-
cable. Our results support the rationale for a substantive
multicenter clinical trial to assess the cost-effectiveness of early
deferred completion of PCI after reperfusion versus conven-
tional treatment in STEMI patients at risk of no-reﬂow.
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